Review Article Advances in pharmacotherapy of Type-2 diabetes (Part-2: The incretin mimetics) (original) (raw)

Type-2 diabetes is witnessing major advances in pharmacotherapy. After a rather dormant period spanning the 1960s and the 1990's following the discovery of the sulphonylureas and biguanide group of drugs, significant advances have been achieved in discovering new drugs. This would not have been possible if not for the advances in biotechnology. In this part of a series of reviews we shall be surfing the first group of the incretin based therapy, the incretin mimetics, exenatide and liraglutide. In a twin paper, the counterpart group of the incretin-based agents, the dipeptidyl peptidase inhibitors DDP-4 antagonists, the gliptins, will also be presented in details.